Compare IFBD & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFBD | PHGE |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 6.9M |
| IPO Year | 2021 | N/A |
| Metric | IFBD | PHGE |
|---|---|---|
| Price | $0.99 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 19.1K | ★ 129.8K |
| Earning Date | 05-01-2023 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,861,442.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1520.48 | N/A |
| 52 Week Low | $0.88 | $1.50 |
| 52 Week High | $2.70 | $22.06 |
| Indicator | IFBD | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 45.62 |
| Support Level | $0.93 | $1.50 |
| Resistance Level | $1.15 | $2.16 |
| Average True Range (ATR) | 0.08 | 0.28 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 20.25 | 23.68 |
Infobird Co Ltd is engaged in developing and providing customer engagement cloud-based services. It software-as-a-service provider of AI-powered, or artificial intelligence-enabled, customer engagement solutions in China. It provides holistic software solutions to help corporate clients proactively deliver and manage end-to-end customer engagement activities at all stages of the sales process, including pre-sales and sales activities, and post-sales customer support. It also offers AI-powered cloud-based sales force management software, including intelligent quality inspection and intelligent training software to help clients monitor, benchmark, and improve the performance of agents.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).